MetaCap

MBX Biosciences (MBX) vs Prestige Consumer Healthcare (PBH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

MBX Biosciences (MBX) has outperformed Prestige Consumer Healthcare (PBH) over the past year, gaining 83.0% versus a loss of 16.5%. MBX Biosciences is the larger company by market cap ($2.46 billion vs $2.35 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

MBX+82.98%PBH-16.48%
+171%+67%-37%
Nov 21, 20251 yearNov 20, 2026
MBX+109.51%PBH-33.04%
+203%+58%-88%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

MBX versus PBH key metrics
MetricMBXPBH
Share price$49.55$49.63
Market cap$2.46B$2.35B
1-day change-7.23%+0.06%
YTD return+57.10%-19.55%
1-year return+82.98%-16.48%
5-year return—-12.02%
P/E ratio (TTM)—15.32
Forward P/E—9.76
EPS (TTM)$-3.03$3.24
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.09B
Revenue growth (YoY)—-4.31%
Net income (latest FY)$-87.00M$190.30M
Gross margin—54.71%
Operating margin—28.42%
Net margin—17.48%
52-week high$72.64$71.07
52-week low$26.14$41.77
Distance from 52-week high-31.79%-30.17%
Analyst consensusstrong_buybuy
Avg. price target upside+91.91%+33.39%
Average volume532.80K583.25K
Shares outstanding49.66M47.40M
Employees63890
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MBX has outperformed PBH by 99.5 percentage points over the past year.

About MBX Biosciences

MBX stock →

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.

Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees

About Prestige Consumer Healthcare

PBH stock →

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare.

Health Care · Biotechnology: Pharmaceutical Preparations · 890 employees

MBX vs PBH FAQ

Which is bigger, MBX Biosciences or Prestige Consumer Healthcare?

MBX Biosciences (MBX) is larger, with a market capitalization of $2.46B compared with $2.35B for Prestige Consumer Healthcare (PBH).

Which stock has performed better over the past year, MBX or PBH?

MBX returned +82.98% over the past 12 months, compared with -16.48% for PBH (price return, excluding dividends). Past performance does not predict future results.

Are MBX Biosciences and Prestige Consumer Healthcare in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons